Revance Therapeutics, Inc. visa sponsorship salaries
Revance Therapeutics, Inc. has 12 certified work-visa filings with a disclosed wage. The median is $150,500; half of filings fall between $137,825 and $181,750. Headquarters on file: Nashville, TN.
Median
$150,500
25th pct
$137,825
75th pct
$181,750
90th pct
$221,650
Filings
12
$111,000$230,000
Salaries by job title
What Revance Therapeutics, Inc. pays by role
| Job title | Filings | 25th | Median | 75th |
|---|---|---|---|---|
| Associate Director, It R&d | 2 | $191,375 | $202,750 | $214,125 |
| Scientist - Process Development | 2 | $141,100 | $141,100 | $141,100 |
| Csv Engineer | 2 | $128,000 | $128,000 | $128,000 |
Locations
Worksites on file
Individual filings
Most recent certified determinations
| Job title | Location | Wage | Prevailing | Level | Decided |
|---|---|---|---|---|---|
| Sr. Specialist, Quality Assurance | Newark, CA | $145,000 | $138,445 | III | Sep 26, 2025 |
| Scientist - Process Development | Newark, CA | $141,100 | $125,278 | II | Aug 7, 2025 |
| Csv Engineer | Newark, CA | $128,000 | $112,091 | II | Jul 3, 2025 |
| Csv Engineer | Newark, CA | $128,000 | $112,091 | II | Jul 3, 2025 |
| Associate Director, It R&d | Newark, CA | $180,000 | $163,509 | I | Jun 27, 2025 |
| Director, It | Newark, CA | $230,000 | $200,304 | II | Jun 23, 2025 |
| Scientist - Process Development | Newark, CA | $141,100 | $137,072 | III | May 13, 2025 |
| Devops Engineer | Livermore, CA | $170,331 | $155,605 | II | Apr 25, 2025 |
| Associate Director, It R&d | Newark, CA | $225,500 | $200,304 | II | Apr 25, 2025 |
| Senior Data Engineer, It Commercial | Newark, CA | $156,000 | $155,605 | II | Jan 29, 2025 |
| Senior Systems Administrator | Newark, CA | $111,000 | $110,032 | II | Nov 22, 2024 |
| Director, Quality Assurance | Newark, CA | $187,000 | $169,666 | III | Oct 25, 2024 |
Wages shown are base salary as filed with the Department of Labor. They exclude bonuses, equity and other compensation, so total pay at Revance Therapeutics, Inc. is typically higher than the figures above.